Flerie Invest AB

FLERIE

SE0022447348

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
46.90 ^SEK	-0.53%		+1.52%	-0.11%

Jul. 10	Nanologica Increases Revenue but Reports Wider Operating Loss	FW
Jul. 03	Flerie's Net Asset Value Rises to SEK 52.78 Per Share in June	FW

Nanologica extends existing loan from Flerie Invest by two years

Published on 03/24/2025 at 09:21

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	FLERIE INVEST AB	46.90SEK	-0.53%	+1.52%	365M
	NANOLOGICA AB	1.140SEK	-3.39%	+2.70%	10.56M

Latest news about Flerie Invest AB

Nanologica Increases Revenue but Reports Wider Operating Loss	Jul. 10	FW
Flerie's Net Asset Value Rises to SEK 52.78 Per Share in June	Jul. 03	FW
Flerie Converts Shares to Series C as Part of Share Redemption Program	Jul. 01	FW
Flerie CEO Ted Fjällman Sells Shares Worth SEK 7.7 Million	Jun. 30	FW
Toleranzia's Delisting Application from First North Approved	Jun. 27	FW
Toleranzia Files for Delisting from Nasdaq First North Growth Market	Jun. 26	MT
Toleranzia Applies for Delisting, Final Trading Day Expected on August 18	Jun. 26	FW
Nanologica Board Recommends Not To Accept Cash Offer Made By Flerie Invest	Jun. 13	RE
Nanologica's board of directors advises against accepting Flerie's mandatory bid offer.	Jun. 13	FW
Nanologica's board of directors advises against accepting Flerie's bid	Jun. 13	FW
Flerie's Nanologica Wins First US Order	Jun. 13	MT
Flerie Portfolio Company Receives First U.S. Order	Jun. 12	RE
Flerie portfolio company Nanologica receives first order in the US	Jun. 12	FW
Flerie's net asset value fell to SEK 50.55 per share in May.	Jun. 04	FW
Flerie's portfolio company Kahr Bio shows positive results in colorectal cancer study	Jun. 03	FW
Flerie's portfolio company presents positive phase II results	Jun. 03	FW
Flerie Invest Announces Mandatory Cash Offer To Shareholders Of Nanologica	May. 23	RE
Flerie makes mandatory bid for Nanologica – offers SEK 1 per share	May. 23	FW
Flerie's portfolio company NorthX Biologics secures growth investment from Signet Healthcare Partners	May. 14	FW
Flerie and Toleranzia receive approval for merger	May. 14	FW
Flerie, Toleranzia General Meetings Approve Merger Plan	May. 14	RE
Toleranzia Approves Merger Plan Adopted By Boards Of Toleranzia, Flerie	May. 07	RE
Flerie's net asset value rose to SEK 50.79 per share in April.	May. 07	FW
Flerie receives regulatory approval for merger with Toleranzia	May. 02	FW
The Stockholm stock exchange continues to climb, with the OMXS30 index rising 0.2 percent.	Apr. 28	FW

Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerieâs investment portfolio.

Employees

Sector

Pharmaceuticals

Calendar

Jul. 31 - Q2 2025 Earnings Release

More about the company